Evidence map›Paper›PMID 35709192›Full record

Observational studyPloS one2022

Clinical characteristics and risk factors for COVID-19 infection and disease severity: A nationwide observational study in Estonia.

Tatjana Meister, Heti Pisarev, Raivo Kolde, Ruth Kalda, Kadri Suija, Lili Milani, Liis Karo-Astover, Marko Piirsoo, Anneli Uusküla

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Observational
  3. Review
  4. Article
  5. Plasma Proteins Associated with COVID-19 Severity in Puerto Rico.International journal of molecular sciences · 2024
    Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Observational
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tatjana MeisterInstitute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.ORCID 0000-0002-4213-6657
Heti PisarevInstitute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Raivo KoldeInstitute of Computer Science, University of Tartu, Tartu, Estonia.
Ruth KaldaInstitute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Kadri SuijaInstitute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
Lili MilaniInstitute of Genomics, University of Tartu, Tartu, Estonia.
Liis Karo-AstoverInstitute of Genomics, University of Tartu, Tartu, Estonia.
Marko PiirsooInstitute of Technology, University of Tartu, Tartu, Estonia.
Anneli UuskülaInstitute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.
University of Tartu · EE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCOVID-19 pandemic has led to overloading of health systems all over the world. For reliable risk stratification, knowledge on factors predisposing to SARS-CoV-2 infection and to severe COVID-19 disease course is needed for decision-making at the individual, provider, and government levels. Data to identify these factors should be easily obtainable. METHODS AND

findingsRetrospective cohort study of nationwide e-health databases in Estonia. We used longitudinal health records from 66,295 people tested positive for SARS-CoV-2 RNA from 26 February 2020 to 28 February 2021 and 254,958 randomly selected controls from the reference population with no known history of SARS-CoV-2 infection or clinical COVID-19 diagnosis (case to control ratio 1:4) to predict risk factors of infection and severe course of COVID-19. We analysed sociodemographic and health characteristics of study participants. The SARS-CoV-2 infection risk was slightly higher among women, and was higher among those with comorbid conditions or obesity. Dementia (RRR 3.77, 95%CI 3.30⎼4.31), renal disease (RRR 1.88, 95%CI 1.56⎼2.26), and cerebrovascular disease (RRR 1.81, 95%CI 1.64⎼2.00) increased the risk of infection. Of all SARS-CoV-2 infected people, 92% had a non-severe disease course, 4.8% severe disease (requiring hospitalisation), 1.7% critical disease (needing intensive care), and 1.5% died. Male sex, increasing age and comorbid burden contributed significantly to more severe COVID-19, and the strength of association for male sex increased with the increasing severity of COVID-19 outcome. The strongest contributors to critical illness (expressed as RRR with 95% CI) were renal disease (7.71, 4.71⎼12.62), the history of previous myocardial infarction (3.54, 2.49⎼5.02) and obesity (3.56, 2.82⎼4.49). The strongest contributors to a lethal outcome were renal disease (6.48, 3.74⎼11.23), cancer (3.81, 3.06⎼4.75), liver disease (3.51, 1.36⎼9.02) and cerebrovascular disease (3.00, 2.31⎼3.89).

conclusionsWe found divergent effect of age and gender on infection risk and severity of COVID-19. Age and gender did not contribute substantially to infection risk, but did so for the risk of severe disease Co-morbid health conditions, especially those affecting renin-angiotensin system, had an impact on both the risk of infection and severe disease course. Age and male sex had the most significant impact on the risk of severe COVID-19. Taking into account the role of ACE2 receptors in the pathogenesis of SARS-CoV-2 infection, as well as its modulating action on the renin-angiotensin system in cardiovascular and renal diseases, further research is needed to investigate the influence of hormonal status on ACE2 expression in different tissues, which may be the basis for the development of COVID-19 therapies.

Indexed as

COVID-19Angiotensin-Converting Enzyme 2COVID-19 TestingEstoniaFemaleHumansMaleObesityPandemicsRetrospective StudiesRisk FactorsRNA, ViralSARS-CoV-2Severity of Illness IndexAngiotensin-Converting Enzyme 2RNA, Viral

Identifiers

PMID35709192
PMCPMC9202832
OpenAlexW4282970335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.